Source:http://linkedlifedata.com/resource/pubmed/id/16094092
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2005-8-11
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-5347
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
174
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1153
|
pubmed:meshHeading |
pubmed-meshheading:16094092-Anti-Bacterial Agents,
pubmed-meshheading:16094092-Ceftriaxone,
pubmed-meshheading:16094092-Child,
pubmed-meshheading:16094092-Dose-Response Relationship, Drug,
pubmed-meshheading:16094092-Humans,
pubmed-meshheading:16094092-Kidney Calculi,
pubmed-meshheading:16094092-Prospective Studies,
pubmed-meshheading:16094092-Risk Factors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Re: Pediatric ceftriaxone nephrolithiasis.
|
pubmed:publicationType |
Letter,
Comment
|